Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Letter to the Editor Sep 2006 Commercial Labs Offer High Quality Services Herman Hurwitz, MD Virtual Mentor. 2006;8(9):C1-C3. doi: 10.1001/virtualmentor.2006.8.9.corr1-0609. Case and Commentary Aug 2006 Dermatology Lab Referrals: Cash Cow or Ethical Trap? Jane M. Grant-Kels, MD and Barry D. Kels, MD, JD Virtual Mentor. 2006;8(8):499-502. doi: 10.1001/virtualmentor.2006.8.8.ccas2-0608. Case and Commentary Aug 2006 Dispensing Cosmeceuticals from the Office Michael H. Gold, MD Virtual Mentor. 2006;8(8):503-508. doi: 10.1001/virtualmentor.2006.8.8.ccas1-0608. Case and Commentary Feb 2007 Risks and Benefits of the New Medical Imaging Enterprise Judy Illes, PhD and Scott W. Atlas, MD Virtual Mentor. 2007;9(2):99-103. doi: 10.1001/virtualmentor.2007.9.2.ccas3-0702. Health Law Dec 2016 The Legal Implications of Detecting Alzheimer’s Disease Earlier Joshua Preston, Jaleh McTeigue, Caitlin Opperman, Jordan Dean Scott Krieg, Mikaela Brandt-Fontaine, Alina Yasis, and Francis X. Shen, JD, PhD What are insurance, contract, and criminal law implications of detecting Alzheimer’s disease early? AMA J Ethics. 2016;18(12):1207-1217. doi: 10.1001/journalofethics.2016.18.12.hlaw1-1612. Health Law Nov 2007 Referral Schemes at Imaging Centers Abigail Van Kempen Virtual Mentor. 2007;9(11):762-764. doi: 10.1001/virtualmentor.2007.9.11.hlaw1-0711. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Letter to the Editor Sep 2006 Commercial Labs Offer High Quality Services Herman Hurwitz, MD Virtual Mentor. 2006;8(9):C1-C3. doi: 10.1001/virtualmentor.2006.8.9.corr1-0609.
Case and Commentary Aug 2006 Dermatology Lab Referrals: Cash Cow or Ethical Trap? Jane M. Grant-Kels, MD and Barry D. Kels, MD, JD Virtual Mentor. 2006;8(8):499-502. doi: 10.1001/virtualmentor.2006.8.8.ccas2-0608.
Case and Commentary Aug 2006 Dispensing Cosmeceuticals from the Office Michael H. Gold, MD Virtual Mentor. 2006;8(8):503-508. doi: 10.1001/virtualmentor.2006.8.8.ccas1-0608.
Case and Commentary Feb 2007 Risks and Benefits of the New Medical Imaging Enterprise Judy Illes, PhD and Scott W. Atlas, MD Virtual Mentor. 2007;9(2):99-103. doi: 10.1001/virtualmentor.2007.9.2.ccas3-0702.
Health Law Dec 2016 The Legal Implications of Detecting Alzheimer’s Disease Earlier Joshua Preston, Jaleh McTeigue, Caitlin Opperman, Jordan Dean Scott Krieg, Mikaela Brandt-Fontaine, Alina Yasis, and Francis X. Shen, JD, PhD What are insurance, contract, and criminal law implications of detecting Alzheimer’s disease early? AMA J Ethics. 2016;18(12):1207-1217. doi: 10.1001/journalofethics.2016.18.12.hlaw1-1612.
Health Law Nov 2007 Referral Schemes at Imaging Centers Abigail Van Kempen Virtual Mentor. 2007;9(11):762-764. doi: 10.1001/virtualmentor.2007.9.11.hlaw1-0711.